Advertisement

Topics

Oncodesign Announces Positive Results Opening the Way for The ALK1 Program to Advance to the Lead Optimization Phase

12:00 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Activin receptor-like kinase 1 (ALK1) is a target involved in angiogenesis with promising applications in cancer therapies The program has identified highly targeted inhibitor molecules and produced p...

Other Sources for this Article

Oncodesign
Philippe Genne
Chairman and CEO
Tel: +33-(0)3-80-78-82-60
investisseurs@oncodesign.com
or
NewCap
Investor & Media Relations
Julien Perez / Nicolas Merigeau
Tel: +33-(0)1-44-71-98-52
oncodesign@newcap.eu

NEXT ARTICLE

More From BioPortfolio on "Oncodesign Announces Positive Results Opening the Way for The ALK1 Program to Advance to the Lead Optimization Phase"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...